

Securities and Exchange Commission  
Office of International Corporate Finance  
100 F Street, N.E., Mail Stop 3628  
Washington DC 20549  
USA

RECEIVED

2008 DEC 30 A 10:25

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

12g-3-2(b) Exemption  
File N° 82-34953



08006352

17<sup>th</sup> November 2008

**SUPPL**

Dear Sir or Madam,

Enclosed is information Ipsen:

- made or is required to make public under French law;
- filed or is required to file with and which is made public by Euronext Paris; or
- distributed or is required to distribute to its shareholders.

This information is being furnished under Paragraph (b)(1)(i) of Rule 12g-3-2 of the Securities Exchange Act of 1934; as amended (the **Exchange Act**), with the understanding that such information and documents will not be deemed "filed" with the U.S. Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter or the furnishing of such documents and information shall constitute an admission for any purpose that Ipsen is subject to the Exchange Act.

Yours sincerely,


*pb*  
Claire Giraut  
Executive Vice President,  
Chief Financial Officer

PROCESSED

JAN 06 2009

THOMSON REUTERS

*llw 4/5*



IPSEN PHARMA

65, QUAI GEORGES GORSE - 92100 BOULOGNE-BILLANCOURT - FRANCE  
TÉL. : +33 (0)1 58 33 50 00 - FAX : +33 (0)1 58 33 50 01  
www.ipsen.com

S.A.S. AU CAPITAL DE 5 707 844 €, R.C.S. NANTERRE 308 197 185  
CODE APE 2120Z, TVA FR 80 308 197 185

Press release

## **Ipsen reinforces its liquidity contract**

- **Additional contribution of €1,000,000**

**Paris, December 17, 2008** - Ipsen (Euronext : FR0010259150; IPN) announced today that it added €1,000,000 to its current liquidity contract.

In accordance to the clause added to the liquidity contract signed on February 19, 2007, Ipsen entrusts Natixis Securities additional means of €1,000,000.

As at June 30, 2008, the following assets appeared on the liquidity account:

- 79,216 Ipsen shares
- €267,624

### **About Ipsen**

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2007, Research and Development expenditure was about €185 million, in excess of 20% of consolidated sales, which amounted to €920.5 million while total revenues amounted to €993.8 million. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at [www.ipсен.com](http://www.ipсен.com)

### **Forward-looking statements**

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the targets described in this document were prepared without taking into account external growth assumptions, as announced on June 5, 2008 and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Furthermore, the Research and Development process involves several stages at each of which there is a substantial risk that the Group will fail to achieve its objectives and be forced to abandon its efforts in respect of a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be

confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

**For further information:**

**Didier Véron**

Director, Public Affairs and Corporate Communications

Tel.: +33 (0)1 58 33 51 16

Fax: +33 (0)1 58 33 50 58

E-mail: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

**David Schilansky**

Investor Relations Officer

Tel.: +33 (0)1 58 33 51 30

Fax: +33 (0)1 58 33 50 63

E-mail: [david.schilansky@ipsen.com](mailto:david.schilansky@ipsen.com)